Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

CHINA PHARMA HOLDINGS, INC.

CIK 1106644 CPHI·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Late filing NT 10-K
  2. Going concern 10-Q +44d
  3. Accounting standard newly cited 10-Q +91d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Going concern Filing comparison

CHINA PHARMA HOLDINGS, INC. no longer discloses a going-concern conclusion

Substantial doubt about ability to continue as a going concern → No going-concern disclosure

Evidence
Blank check
No
Comparable
Yes
Current state
none
Current state label
No going-concern disclosure
Direction
eased
Prior filed
2026-05-15
Prior form
10-Q
Prior state
substantial_doubt
Prior state label
Substantial doubt about ability to continue as a going concern
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Accounting standard newly cited Filing comparison

CHINA PHARMA HOLDINGS, INC. cited accounting standard ASU 2016-13 for the first time in this filing series

The Company adopted ASU 2016-13 Financial Instruments — Credit Losses (ASC Topic 326): Measurement of Credit Losses on Financial Instruments, which replaced the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology.
Evidence
Adopted
2016-13
Contexts
The Company adopted ASU 2016-13 Financial Instruments — Credit Losses (ASC Topic 326): Measurement of Credit Losses on Financial Instruments, which replaced the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology.
New standards
2016-13
Prior filed
2026-05-15
Prior form
10-Q
Restates existing policy
No
Source
accounting standards update (ASU) reference comparison
Why
The summary of significant accounting policies changed materially from the previous comparable filing.

Source filing ↗ Prior filing ↗

Going concern Filing comparison

CHINA PHARMA HOLDINGS, INC. disclosed substantial doubt about its ability to continue as a going concern

Substantial doubt raised, alleviated by management's plans → Substantial doubt about ability to continue as a going concern

As of March 31, 2026, the Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer, Ms. Li, has advanced an aggregate of $1,466,145 to provide working capital and enabled the Company to make the required payments related to its former construction loan facility and current lines of credit. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
going-concern note
Prior filed
2025-11-12
Prior form
10-Q
Prior state
doubt_alleviated
Prior state label
Substantial doubt raised, alleviated by management's plans
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Late filing elevated Filing comparison

CHINA PHARMA HOLDINGS, INC. told the SEC it could not file its annual report on time

The compilation, dissemination and review of the information required to be presented in the annual report on Form 10-K for the fiscal year ended December 31, 2025 (the “Annual Report”) imposed time constraints that have rendered timely filing of the Annual Report impracticable without undue hardship and expense to the registrant.
Evidence
Days past due date
1
Other periodic reports filed
Yes
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
The compilation, dissemination and review of the information required to be presented in the annual report on Form 10-K for the fiscal year ended December 31, 2025 (the “Annual Report”) imposed time constraints that have rendered timely filing of the Annual Report impracticable without undue hardship and expense to the registrant.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗